Search

Displaying results 3321 - 3330 of 9132 in total
  1. Drug

    Tulrampator

    go.drugbank.com/drugs/DB16344
    Investigational

    Tulrampator is under investigation in clinical trial NCT02626572 (Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive

  2. Drug

    EU204

    go.drugbank.com/drugs/DB17438
    Investigational

    EU204 (EBViNT) is an Epstein-Barr virus (EBV)-positive T-cell therapy currently undergoing phase 1 and 2a clinical trials in Korea for patients with EBV-positive lymphoma and solid cancer.

  3. Drug

    FB-101

    go.drugbank.com/drugs/DB17956
    Investigational

    FB-101 is a c-Abl inhibitor. … Developed by 1st Biotherapeutics, it is being investigated for the treatment of neurological disorders, such as Parkinson's Disease and amyotrophic lateral sclerosis (ALS).[L47102]

  4. Drug

    (R)-Fluoxetine

    go.drugbank.com/drugs/DB08472
    Experimental

    An N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine that has R configuration (the antidepressant drug fluoxetine is a racemate comprising equimolar amounts of (R)- and (S)-fluoxetine).

  5. Drug

    (S)-Fluoxetine

    go.drugbank.com/drugs/DB08544
    Experimental

    An N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine that has S configuration (the antidepressant drug fluoxetine is a racemate comprising equimolar amounts of (R)- and (S)-fluoxetine).

  6. Drug

    Bosutinib

    go.drugbank.com/drugs/DB06616
    ApprovedInvestigational

    Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive … [A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  7. Drug

    Brexucabtagene autoleucel

    go.drugbank.com/drugs/DB15699
    ApprovedInvestigational

    Mantle cell lymphoma (MCL) is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. … [A216148, A216163, L15148] However, the preparation of brexucabtagene autoleucel, previously referred to as KTE-X19, uses a method of T cell enrichment that decreases the prevalence of CD19-expressing

  8. Drug

    Molsidomine

    go.drugbank.com/drugs/DB09282
    ApprovedWithdrawn

    Interestingly, it is being studied as being a preventive measure in cerebral infarction [A31932]. … Molsidomine is an orally active, long-acting vasodilator, which belongs to the class of medications known as syndnones.

  9. Drug

    Levosimendan

    go.drugbank.com/drugs/DB00922
    ApprovedInvestigationalWithdrawn

    Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Ichthammol

    go.drugbank.com/drugs/DB11341
    Approved

    It is available in OTC products as an active ingredient for the treatment of skin disorders such as eczema, psoriasis and boils as it is thought to exhibit anti-inflammatory, antibacterial and antimycotic … Ichthammol is also referred to as ammonium bituminosulfonate or ammonium bituminosulphonate.